Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
NCT ID: NCT01379833
Last Updated: 2019-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18 participants
OBSERVATIONAL
2011-05-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa
NCT02513485
Neurofeedback in Patients With Frontal Brain Lesions
NCT02957695
Psychiatric Comorbidities in Patients With Painful Peripheral Neuropathy
NCT03275233
Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders
NCT05212727
Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.
NCT07234851
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CIDP may affect any nerve plexus in the body. However, diagnostic criteria leans towards nerve conduction studies in the limbs and denervation in other organ systems might be overlooked. Sensory innervation of the cornea is provided by the ophthalmic branch of the trigeminal nerve via the anterior ciliary nerves. A relatively small number (50-450) of primary sensory neurons from the ipsilateral trigeminal ganglion send their peripheral axons to the cornea and branch extensively within the corneal tissue. To maintain corneal transparency, all peripheral axons of corneal neurons lose the myelin sheath when they enter the corneal stroma. Fibers spread in a radial fashion parallel to the corneal surface.1
Our proposed study will explore the relationship of decreased corneal sensation, a potentially devastating eye condition secondary to CIDP. Decreased corneal sensation may lead to neurotrophic keratitis; which describes corneal diseases due to impairment or loss of corneal sensation leading to epithelial defects and corneal ulcers. This may be caused by many ocular and systemic diseases such as Diabetes or Stroke. Corneal innervation is important for the maintenance of corneal structure and function, and provides protective mechanisms against factors that might be potentially damaging to the cornea. Innervation also plays an important trophic function in corneal repair in relation to disease, trauma or surgery. Denervation and decreased corneal sensitivity are associated with impairment of epithelial and endothelial cell function, increased epithelial and endothelial permeability, decreased cell migration and cell mitosis. In addition, denervated corneas are predisposed to epithelial or stromal abnormalities, recurrent erosion, impaired wound healing and infection.2
Although corneal nerves lose their myelin sheath as they enter the stroma, the association of a demyelinating disease affecting these nerves cannot be excluded. This may be because trigeminal nerves can be affected at different levels (the nucleus in the pons, the Gasserian ganglion, the trigeminal ophthalmic branch, the nasociliary nerve, or the long ciliary nerve). Also, nerves without central myelin throughout their length can be affected in CIDP. For example, CNVIII has peculiar myelin as it has central myelin for the majority of its length, except for a short distal segment which has peripheral myelin.6 There is one case report correlating findings of hearing loss and vestibular dysfunction for over a 6-year period in patients with CIDP.
OUR STUDY
We plan a prospective clinical trial to compare prevalence of decreased corneal sensation and possible decrease in corneal nerves in patients with CIDP previously diagnosed by clinical features and electrophysiologic data as outlined by the American Academy of Neurology10 as compared to patients without CIDP. Patients will be categorized according to the severity of the disease and duration as per their medical records. Exclusion criteria is aimed at those conditions which may reduce corneal sensation such as previous eye trauma, surgery, contact lens use, eye drop use, or previous viral infections of the eye. A routine complete eye exam will be performed along with additional testing for corneal sensation using a standard method. If significant findings are obtained during initial eye exam, subjects will obtain in-vivo confocal imaging at a second site to image corneal nerve fibers. Published standards for corneal sensitivity as well as corneal nerve fiber density via confocal imaging will be used in statistical analysis.
SIGNIFICANCE OF THIS STUDY
Experimental evidence indicates that impairment of corneal sensory nerves induces pathological changes in the anatomic integrity and function of the cornea, particularly in the epithelium. Loss of corneal sensory innervations leads to a decrease in thickness of the corneal epithelium, intracellular swelling, loss of microvilli and abnormal production of the basal lamina. This may lead to impairment in vitality, metabolism, and mitosis of epithelial cells and, consequently, epithelial breakdown. Persistent epithelial defects may lead to chronic ulceration and eventually to compromise of all ocular surface components with severe visual impairment.
If an association is found between CIDP and decreased corneal sensation, this study will be the first one to demonstrate such an association. An increased awareness among physicians about this association may lead to a more careful eye exam in patients with CIDP and detection of early changes of ocular disease which may be treated earlier so that serious blinding complications can be avoided.
FUTURE STUDIES
If a positive association is found between CIDP and decreased corneal sensation, the latter may be added as a supportive criteria in grading the severity of CIDP. CIDP has many treatment modalities available according to its severity and clinical course. Finding decreased corneal sensation in CIDP patients prospectively may lead to a diagnosis of increased disease severity and patients may benefit from more aggressive treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects
Subjects are patients with CIDP
No interventions assigned to this group
Controls
Controls are age-matched people without CIDP
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
110 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dent Neurological Institute, Buffalo, NY
UNKNOWN
Fichte, Endl & Elmer Eyecare
OTHER
State University of New York at Buffalo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sangita Patel
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Surbhi Bansal, M.D.
Role: PRINCIPAL_INVESTIGATOR
Ross Eye Institute, University at Buffalo
Sangita Patel, M.D. PhD.
Role: STUDY_DIRECTOR
Ross Eye Institute, University at Buffalo
Thomas Elmer, M.D.
Role: STUDY_DIRECTOR
Fichte, Endl & Elmer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dent Neurological Institute
Buffalo, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
1. Bonini S et al. Neurotrophic Keratitis. Contemporary Ophthalmology. 2008. 7(2): 1-8. 2. Grupcheva CH et al. Assessing the sub-basal nerve plexus of the living healthy human cornea by in vivo confocal microscopy. Clinical and Experimental Ophthalmology. 2002, 30: 187-190. 3. Malik RA et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003. 46: 683-688. 4. Merkies IS et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst. 2010 Sep;15(3):208-15. 5. Nobile-Orazio E et al. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Current Opinion in Neurology. 2010; 23: 519-523. 6. Oh SJ. Color Atlas of Nerve Biopsy Pathology. 1st Edition. CRC Press LLC, Boca Raton, Florida. Copyright 2002. 7. Patel DV et al. Contemporary in vivo confocal microscopy of the living human cornea using white light and laser scanning techniques: a major review. Clinical and Experimental Ophthalmology 2007; 35: 71-88. 8. Rajabelly YA et al. Electrophysiological sensory demyelination in typical chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology 2010, 17: 939-944. 9. Van den Bergh PYK et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. European Journal of Neurology. 2010, 17: 356-363. 10. American Academy of Neurology.
Bansal S, Myneni AA, Mu L, Myers BH, Patel SP. Corneal sensitivity in chronic inflammatory demyelinating polyneuropathy. Cornea. 2014 Jul;33(7):703-6. doi: 10.1097/ICO.0000000000000145.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPT0120511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.